
More Intense First-Line Chemo Improves Outcome in Advanced Colorectal Cancer
By Megan Brooks NEW YORK (Reuters Health) - Patients with advanced colorectal cancer fare better with first-line treatment with FOLFOXIRI (folinic acid, 5-FU, oxaliplatin and irinotecan) plus bevacizumab than with FOLFIRI (folinic acid, 5-FU and irinotecan) plus bevacizumab, according to updated survival results from the Italian TRIBE study.

